Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injecti… Read more
Market Cap & Net Worth: Sino Biopharmaceutical Limited (SBMFF)
Sino Biopharmaceutical Limited (PINK:SBMFF) has a market capitalization of $8.12 Billion ($8.12 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #3279 globally and #2180 in its home market, demonstrating a 1.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sino Biopharmaceutical Limited's stock price $0.45 by its total outstanding shares 17885721987 (17.89 Billion).
Sino Biopharmaceutical Limited Market Cap History: 2015 to 2025
Sino Biopharmaceutical Limited's market capitalization history from 2015 to 2025. Data shows growth from $5.32 Billion to $8.12 Billion (4.30% CAGR).
Sino Biopharmaceutical Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sino Biopharmaceutical Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.26x
Sino Biopharmaceutical Limited's market cap is 0.26 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.14x
Sino Biopharmaceutical Limited's market cap is 2.14 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.32 Billion | $12.18 Billion | $1.49 Billion | 0.44x | 3.57x |
| 2016 | $4.75 Billion | $14.17 Billion | $1.71 Billion | 0.34x | 2.77x |
| 2017 | $11.48 Billion | $14.82 Billion | $2.17 Billion | 0.77x | 5.29x |
| 2018 | $6.62 Billion | $20.89 Billion | $9.05 Billion | 0.32x | 0.73x |
| 2019 | $15.01 Billion | $24.23 Billion | $4.69 Billion | 0.62x | 3.20x |
| 2020 | $15.27 Billion | $23.65 Billion | $2.77 Billion | 0.65x | 5.51x |
| 2021 | $10.73 Billion | $26.86 Billion | $14.61 Billion | 0.40x | 0.73x |
| 2022 | $9.69 Billion | $26.03 Billion | $2.54 Billion | 0.37x | 3.81x |
| 2023 | $7.14 Billion | $26.20 Billion | $2.33 Billion | 0.27x | 3.06x |
| 2024 | $7.48 Billion | $28.87 Billion | $3.50 Billion | 0.26x | 2.14x |
Competitor Companies of SBMFF by Market Capitalization
Companies near Sino Biopharmaceutical Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Sino Biopharmaceutical Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Sino Biopharmaceutical Limited Historical Marketcap From 2015 to 2025
Between 2015 and today, Sino Biopharmaceutical Limited's market cap moved from $5.32 Billion to $ 8.12 Billion, with a yearly change of 4.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $8.12 Billion | +8.56% |
| 2024 | $7.48 Billion | +4.71% |
| 2023 | $7.14 Billion | -26.31% |
| 2022 | $9.69 Billion | -9.64% |
| 2021 | $10.73 Billion | -29.72% |
| 2020 | $15.27 Billion | +1.72% |
| 2019 | $15.01 Billion | +126.60% |
| 2018 | $6.62 Billion | -42.28% |
| 2017 | $11.48 Billion | +141.66% |
| 2016 | $4.75 Billion | -10.76% |
| 2015 | $5.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Sino Biopharmaceutical Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.12 Billion USD |
| MoneyControl | $8.12 Billion USD |
| MarketWatch | $8.12 Billion USD |
| marketcap.company | $8.12 Billion USD |
| Reuters | $8.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.